MitoPharm Corporation’s Test Findings Support the Notion That Schisandrin B Serves as an All-Round Protecting Agent Against Free Radical-Induced Cellular Injury

SEATTLE--(BUSINESS WIRE)--MitoPharm Corporation, Inc. (Pink Sheets:MTPM), releases the results of a research paper where Professor Dr. Robert Ko defines the molecular mechanism of Schisandrin B, the precursor of (-) Schisandrin B - a novel discovery by Dr. Ko – which explains the enhancement of cellular or mitochondrial Glutathione status.